Introduction {#s0005}
============

Epithelial ovarian cancer (EOC) accounts for the majority of mortality from gynecological cancers, with diagnosis often at a late stage. Currently, the golden standard of treatment is primary debulking surgery (PDS) followed by platinum-based chemotherapy [@bb0005]. Although most patients initially respond to chemotherapy, cancer cells will eventually develop resistance leading to relapse [@bb0010]. Despite intensive efforts to improve targeted therapy in EOC, the five-year survival rate is still only 30% for advanced disease [@bb0015]. Therefore, increased knowledge about mechanisms of platinum resistance in EOC treatment is needed in search for cure.

Genetically complex and unstable high-grade serous ovarian cancer subtype (HGSC), accounting for approximately 50--70% of EOC, represents the most aggressive histological subtype [@bb0020]. A large-scale integrated genomic data analysis for HGSC identified TP53 mutations in almost 96% of tumors. Recurrent somatic mutations were found in nine other genes including NF1, BRCA1, BRCA2, RB1 and CDK12, as well as DNA copy number aberrations and promoter methylation events, indicating biological and molecular heterogeneity that should be considered when developing novel therapeutic strategies [@bb0025].

While only 10%--15% of ovarian cancer patients carry BRCA1 or BRCA2 mutations in their germline, ∼50% of ovarian cancers exhibit a defect in the homologous recombination (HR) repair of DNA [@bb0030]. PARP-1 enzyme became an attractive target for chemotherapeutics for its crucial function in single-strand breaks (SSBs) DNA repair mechanism through base excision repair (BER) pathway [@bb0035]. The concept of synthetic lethality has been used in genetic studies to determine functional interactions and compensation among genes for decades and has also been exploited in the development of PARP (Poly (ADP-ribose) polymerase) inhibitors [@bb0040]. The responsiveness to platinum and PARP inhibitors associates with so called *BRCAness* profile showing independent prognostic value [@bb0045], [@bb0050].

The chemotherapy resistance can arise due to multiple mechanisms, such as drug target alteration, re-activation or amplification of the oncogenic pathway, activation of parallel pathways, increased DNA damage tolerance/repair, and deregulation of growth factor receptors among others [@bb0055]. Deregulation of apoptosis and altered phosphorylation (intracellular signaling), as well as metabolic pathways represent the two main biological processes responsible for oncogene-mediated drug resistance in ovarian cancer [@bb0060]. In this context, activation of PI3K/AKT cell survival pathway plays a pivotal role with NF-kB and STAT3 as the main mediations of these intracellular events. On the other hand, tumor suppressor genes such as BRCA1, BRCA2, MLH1 and p21 contribute to ovarian cancer drug resistance via alterations in the DNA damage and repair mechanisms, whereas RASSF1, TP53 and TP73 impair the apoptotic machinery for the same outcome [@bb0065]. Epithelial-to-mesenchymal transition (EMT) has also been implicated in HGSC invasiveness and chemoresistance, and in vitro studies using ovarian cancer cell lines have shown that more aggressive, mesenchymal-type cells are more resistant to cisplatin treatment [@bb0070]. An important signaling cascade involved in EMT is the Wnt signaling, with increasing evidence suggesting that β-catenin-independent pathway via Wnt5a/ROR1/ROR2 has a critical role in EMT and chemoresistance [@bb0075], [@bb0080], [@bb0085], [@bb0090]. Consequently, therapies targeting these pathways may offer means to overcome drug resistance.

Active and also productive research in the field of cancer therapy has led to an improved understanding of the molecular mechanisms, providing insight into the development of cancer. This new data has led to the development of new treatment options for cancer patients, including targeted therapies and associated biomarker tests that can select which patients are most likely to respond [@bb0095]. The aim of this study was to identify candidate genes and their molecular pathways involved in the pathogenesis of ovarian cancer associating with platinum resistance. Overcoming the paucity of obtaining large collection of tumor samples available for molecular profiling, we investigated differences in mRNA and protein expression between ovarian cancer samples derived from two clinically and molecularly distinct patient cohorts namely high PARP/platinum-sensitive and low PARP/platinum-resistant HGSC cohorts. This comparison aimed at distinction of two cohorts with extremely different clinical behavior. Finally, this analysis led to identification of GREB1 and ROR2 that showed significant differential expression profile between the two groups. Our data suggest new predictive biomarkers for ovarian cancer drug resistance development warranting further investigations.

Materials and Methods {#s0010}
=====================

Study Cohort and Tissue Samples {#s0015}
-------------------------------

The study was carried out at the University of Tampere and Tampere University Hospital (TAUH), Tampere, Finland. The study protocol was approved by the Ethics Committee of TAUH (identification code ETL-R11137).

The microarray study cohort consisted of 12 HGSC patients who participated in a prospective study addressing PARP enzyme activity in fresh ovarian cancer tumor samples [@bb0100]. The selection of this patient subcohort was based on PARP values (high PARP/low PARP, cut off 203 pg/ml, which corresponded to the median value of PARP) and platinum sensitivity/resistance (treatment response), with no differences in respect of age and FIGO (International Federation of Gynecology). Platinum sensitivity was defined as no recurrence within 12 months after the completion of first-line platinum-based chemotherapy. Patient characteristics are presented in [Table 1](#t0005){ref-type="table"}.Table 1Characteristics of the Study Patients in the Microarray Cohort (n = 12)Table 1CharacteristicPlatinum Sensitive[\*](#tf0005){ref-type="table-fn"} n (%)Platinum Resistant[\*](#tf0005){ref-type="table-fn"} n (%)All66PDS[†](#tf0010){ref-type="table-fn"}52NACT[‡](#tf0015){ref-type="table-fn"}14PARP[§](#tf0020){ref-type="table-fn"} low06PARP[§](#tf0020){ref-type="table-fn"} high60Age mean (SD)6562 median (range)63 (46--78)62 (55--79) Grade 3[¶](#tf0025){ref-type="table-fn"}6 (100%)6 (100%)Stage[\#](#tf0030){ref-type="table-fn"} FIGO st I00 FIGO st II00 FIGO st III and IV66Histology serous6 (100%)6 (100%) PFS[\*\*](#tf0035){ref-type="table-fn"} (months)283.5[^2][^3][^4][^5][^6][^7][^8]

The validation cohort of the microarray data consisted of all the patients (n = 53) that participated in the previous prospective study [@bb0100]. The median follow-up time of patients was 31 months. The validation cohort is described in [Table 2](#t0010){ref-type="table"}.Table 2Characteristics of the Study Patients in the Validation Cohort (n = 53)Table 2CharacteristicPatients in study, n53Age at surgery, yrs. (SD)66 (9.3)BMI, mean (SD)26.8 (6.2)Median follow-up, months (range)31 (2--50)Ca 125 level (kU/L) before treatment, median (range)523 (30--4728)FIGO[\*](#tf0040){ref-type="table-fn"} Stage, n (%) Stage 12 (3,7%) Stage 23 (5,6%) Stage 334 (64,3%) Stage 414 (26,4%)Histology, n (%) Serous46 (86,8) Endometroid4 (7,6%)Papillar2 (3,7%) Mucinous0 (0%) Carcinosarcoma0 (0%)Transitional cell1 (1,9%)Grade[†](#tf0045){ref-type="table-fn"}, n (%) Grade 1 and 210 (18%) Grade 343 (82%)Sensitivity to platinum therapy[‡](#tf0050){ref-type="table-fn"}, n (%) Sensitive25 (47,2%) Resistant15 (28,3%) Partial sensitive13 (24,5%)Neoadjuvant therapy, n (%)19 (36%)Recurrence36 (68%)Death22 (42%)[^9][^10][^11]

For further investigation of ROR2 in EOC, a retrospective subcohort was chosen from the study cohorts described above consisting of a subgroup of patients who had not received NACT (neoadjuvant chemotherapy) and were divided in two categories based on treatment response, i.e. either platinum-sensitive or platinum-resistant ([Table 3](#t0015){ref-type="table"}).Table 3Characteristics of the study patients in the ROR investigation subcohort (n = 30)Table 3CharacteristicPatients in study, n30Age at surgery, yrs mean (SD)66 (9.3)Median follow-up, months (range)31 (2--50)FIGO[\*](#tf0055){ref-type="table-fn"} Stage, n (%) Stage 12 (6,7%) Stage 24 (14%) Stage 317 (56%) Stage 47(23,3%)Histology, n (%) Serous22(73,3%) Endometroid2 (6,7%)Papillar2 (6,7%) Mucinous2 (6,7%) Carcinosarcoma1 (3,3%)Transitional cell1 (3,3%)Grade[†](#tf0060){ref-type="table-fn"}, n (%) Grade 1 and 28 (26,7%) Grade 322 (73,3%)Response to platinum therapy[‡](#tf0065){ref-type="table-fn"}, n (%) Sensitive20 (66,7%) Resistant10 (33,3%)Recurrence20 (66,7%)Death9 (30%)[^12][^13][^14]

The tumor tissue samples were collected at surgery, two samples approximately 0.5 cm were chosen at the operation room from macroscopically visible tumor and were snap-frozen with liquid nitrogen and stored in −70 °C. The findings from the corresponding archival surgical tumor specimens were assessed by experienced pathologists as part of routine diagnostics at the Department of Pathology at TAUH.

mRNA Microarray {#s0020}
---------------

Total RNA from ovarian cancer fresh frozen samples was extracted using TRIzol reagent (Invitrogen, Carlsbad, CA, USA), according to the manufacturer\'s protocol. The quality and integrity of the RNA was assessed using Fragment Analyzer parallel capillary electrophoresis (Advanced Analytical Technologies, Ankeny, IA, USA). The RNA was subsequently labeled and hybridized using the Agilent gene expression microarray kit (Agilent Technologies, Santa Clara, CA, USA), according to the manufacturer\'s instruction. Briefly, the RNA from the clinical samples was labeled with Cy3 fluorochrome and subsequently co-hybridized with Cy5 labeled Xpress Ref TM Human Universal Reference Total RNA (SuperArray Bio-science Corporation) as a control. The hybridization was carried out for 21 hours on Agilent 4X44K human gene expression array slides. The slides were subsequently scanned on an Agilent C scanner and raw data were extracted using the Agilent Feature Extraction software ver. 11.0.1.1 and quantile normalized. A fold-change cutoff of 2 was used to determine differential mRNA expression as well as q-value and signal intensity.

qRT-PCR {#s0025}
-------

Putatively differentially expressed genes (*ROR2, CAST, ATP6V1D, GUCY1A3, TMOD1, MYCN, DLK1, PLEKHG4B, GREB1, B4GALNT4, SLC35F3, PTCH2, TNNC1, BNC1*) were selected from the array results based on fold change, q-value, signal intensity and literature data and were validated by quantitative real-time polymerase chain reaction (qRT-PCR). Total RNA from ovarian cancer fresh frozen tumor samples were extracted with TRIzol as described above and were reverse transcribed using random hexamere primers and MultiScribe reverse transcriptase (Thermo Fischer Scientific, Waltham, MA, USA). Quantitative Real Time PCR was performed using Maxima SYBR Green/ROX qPCR Master Mix (Thermo Fischer Scientific) on a BioRad CFX96 ™ Real-Time PCR Detection System (BioRad Laboratories, Hercules, CA, USA). Each sample was run in duplicate and expression values were normalized against the TATA-binding protein (TBP). The primer sequences for the two validated genes are as follows:Unlabelled TableGREB1 fw5'ATGGGAAATTCTTACGCTGGACGREB1 rev5'CACTCGGCTACCACCTTCTROR2 fw5'GTGCGGTGGCTAAAGAATGATROR2 rev5'ATTCGCAGTCGTGAACCATATTTBP fw5'GAATATAATCCCAAGCGGTTTGTBP rev5'ACTTCACATCACAGCTCCCC

Western blotting {#s0030}
----------------

Frozen tumor pieces were thawed, washed 2X with cold PBS and pestered to lyse in lysis buffer (50 mM Tris--HCl pH 7.5, 10% glycerol, 150 mM NaCl, 1 mM EDTA, 1% Triton-x-100, 50 mM NaF) supplemented with protease and phosphatase inhibitor cocktails (Bimake, Houston, TX, USA). Lysates were mixed with 4X Laemmli loading buffer and subjected to SDS-PAGE gel electrophoresis and Western blotting. The primary antibodies used were as following: pAkt S473 (\#4060), pMEK1/2 S217/221 (\#9121), NF-κB p65 (\#6956), pPI3K p85 Y458/p55 Y199 (\#4228), PI3K p85α (\#13666), Rac-1 (\#4651), pSTAT3 Y705 (\#9145), STAT3 (\#9139), Wnt5a/b (\#2530) (Cell Signaling Technology, Danvers, MA, USA); Akt (\#sc-5298), Bcl-2 (\#sc-7382), MEK1/2 (\#sc-6250), β-tubulin (\#sc-166,729) (Santa Cruz, Dallas, TX, USA); ROR1 6D4 (Dr. Riddel lab, ref. Balakrishana et al. 2016); ROR2 (\#565550, BD Biosciences, San Jose, CA, USA). Secondary antibodies: IRDye® 800CW Donkey anti-Mouse IgG, or IRDye® 680RD Donkey anti-Rabbit IgG (LI-COR, Lincoln, NE, USA). Blots were scanned and quantified using Odyssey CLx and Image Studio software (LI-COR). Protein quantification was normalized to β-tubulin expression level for each sample.

Cell Culture {#s0035}
------------

A2780 and A2780cis cells were purchased from Merck & Company Inc. (Kenilworth, NJ, USA) and cultured according to manufacturer\'s recommendations. The A2780 line was maintained in medium containing 1 μM cisplatin (Selleckchem, Munich, Germany). The cisplatin EC50 response of A2780 and A2780cis cells was validated by incubating cells with increasing concentration of cisplatin for 3 days and cell viability was determined using CellTiterGlo (CTG) Assay (Promega, USA) according to manufacturer\'s instructions.

qRT-PCR of the Ovarian Cancer Cell Lines {#s0040}
----------------------------------------

RNA was collected from A2780 and A2780cis using TRI Reagent® (Molecular Research Center Inc. Cincinnati, OH, USA) according to the manufacturer\'s protocol. qRT-PCR was performed as described for the ovarian cancer clinical samples. Each cell line was run in 4 replicates and the expression of ROR2 and GREB1 was normalized against TBP.

Statistical Analysis {#s0045}
--------------------

The statistical analysis of mRNA microarray data was implemented in R using packages limma and preprocessCore of Bioconductor project [@bb0105], [@bb0110], [@bb0115]. Data was quantile normalized and probe sets were summarized by choosing the probes with the highest average expression [@bb0110]. Using limma approach, differential expression was identified between patients who had low PARP value and were platinum resistant, and patients who had high PARP value and were platinum sensitive [@bb0115]. P-values were obtained by the empirical Bayes moderated t-test. A fold-change cutoff of 2 was used to determine differential mRNA expression. The results were interpreted by principal component analysis [@bb0120] and hierarchical clustering.

qRT-PCR data were analyzed using the Student\'s t-test and Mann--Whitney U test where appropriate. The Kaplan--Meier regression analyses were used to estimate the survival rates from the date of surgery (primary debulked patients) or from the date of the first dose of neoadjuvant therapy until the date of the event of interest. For progression-free survival (PFS), the event of interest was a recurrence or death, whichever occurred first. Patients alive at the last follow-up without a recurrence were censored at the last follow-up date. Statistical analysis was performed using GraphPad Prism 6 software for Windows (GraphPad Software Inc., La Jolla, CA, USA). A p-value less than 0.05 was considered significant.

Oncomine (<https://www.oncomine.org/resource/login.html>) and Kaplan--Meier plotter (<http://kmplot.com/analysis/index.php?p=service&cancer=ovar>) databases were searched for gene expression and survival data.

Results {#s0050}
=======

Microarray Analysis of HGSC Patient Samples {#s0055}
-------------------------------------------

In order to identify differentially expressed genes between ovarian cancer samples with platinum-sensitivity with high PARP levels and samples with platinum resistance with low PARP levels (n = 12), gene expression microarray was performed on total RNA isolated from the freshly frozen tumor samples. The analysis of gene expression showed a total of 3001 differentially expressed genes between the two comparison groups when a log fold change cutoff 2 was implemented. In this comparison, 1463 genes were downregulated and 1538 genes were upregulated. 50 most upregulated and 50 most downregulated genes are summarized in [Table 4](#t0020){ref-type="table"}, [Table 5](#t0025){ref-type="table"}, respectively. The comparison of patient groups according to PARP levels and treatment responses are shown in [Figure 1](#f0005){ref-type="fig"}, a-b.Table 4The 50 Most Upregulated mRNAs in High PARP and Platinum Sensitive OC Patient Samples in Comparison to low PARP and Platinum Resistant Samples.Table 4Gene nameGene descriptionlog2-fold changep-valueq-valueCOLEC11collectin subfamily member 113.68E+ 001.29E-020.2588936**MYCNMYCN proto-oncogene. bHLH transcription factor3.61E+** **002.74E-040.1050305**ESM1endothelial cell specific molecule 13.18E+ 001.64E-040.1028588IGF1Rinsulin like growth factor 1 receptor3.08E+ 005.29E-030.211962**TNNC1troponin C1. slow skeletal and cardiac type3.04E+** **001.25E-050.0472319**LGSNlengsin. Lens protein with glutamine synthetase domain3.02E+ 001.25E-020.2588936LOC100134423uncharacterized LOC1001344232.97E+ 002.71E-040.1050305**DLK1delta like non-canonical Notch ligand 12.89E+** **004.17E-030.2013983**CRYGCcrystallin gamma C2.86E+ 002.37E-030.1822358A_33_P3286709NA2.82E+ 009.15E-050.0864965**PLEKHG4Bpleckstrin homology and RhoGEF domain containing G4B2.82E+** **001.17E-030.1525447**TSPAN8tetraspanin 82.78E+ 002.99E-020.3064189ENPP6ectonucleotide pyrophosphatase/phosphodiesterase 62.73E+ 001.20E-020.2563874FLJ30901uncharacterized protein FLJ309012.60E+ 003.26E-040.1050305PROM1prominin 12.59E+ 003.02E-020.3079072COL22A1collagen type XXII alpha 1 chain2.58E+ 002.64E-030.1844765KIAA1324KIAA13242.58E+ 005.48E-040.1261184**PTCH2patched 22.57E+** **001.93E-050.0472319SLC35F3solute carrier family 35 member F32.54E+** **003.87E-050.0596903**GABRG3gamma-aminobutyric acid type A receptor gamma3 subunit2.51E+ 004.50E-050.0628517LOC613266uncharacterized LOC6132662.50E+ 004.89E-020.3485897LCE1Elate cornified envelope 1E2.49E+ 002.28E-040.1050305**B4GALNT4beta-1.4-N-acetyl-galactosaminyltransferase 42.49E+** **001.24E-050.0472319**STC2stanniocalcin 22.48E+ 002.86E-040.1050305FOXL2NBFOXL2 neighbor2.48E+ 001.04E-010.4447586AK124496NA2.47E+ 002.78E-020.3020977CU677518NA2.47E+ 002.82E-060.0275612NM_130777NA2.45E+ 001.10E-020.2525629NR_102701NA2.43E+ 002.11E-030.1762016NSG1neuronal vesicle trafficking associated 12.43E+ 001.05E-030.1525447STARsteroidogenic acute regulatory protein2.41E+ 005.08E-030.2110634MCTS2Pmalignant T-cell amplified sequence 2. pseudogene2.40E+ 005.43E-030.2134259TRABD2ATraB domain containing 2A2.36E+ 004.89E-030.2078187DEPTORDEP domain containing MTOR interacting protein2.35E+ 004.70E-040.125416CLEC4GP1C-type lectin domain family 4 member G pseudogene 12.35E+ 004.56E-030.2021535LINC01405long intergenic non-protein coding RNA 14052.33E+ 006.95E-040.1391319COL2A1collagen type II alpha 1 chain2.32E+ 001.82E-020.2816697HS6ST2heparan sulfate 6-O-sulfotransferase 22.31E+ 002.15E-020.2871745PRAMEpreferentially expressed antigen in melanoma2.30E+ 004.32E-050.0628517LINC02398long intergenic non-protein coding RNA 23982.29E+ 001.08E-050.0472319GJB7gap junction protein beta 72.29E+ 003.18E-020.3122712PLCXD3phosphatidylinositol specific phospholipase C X domain containing 32.28E+ 006.03E-020.3707384ERVI-1endogenous retrovirus group I member 12.27E+ 001.28E-020.2588936ZNF556zinc finger protein 5562.27E+ 001.46E-060.0213888NTSneurotensin2.26E+ 006.56E-020.3828556BU963192NA2.25E+ 007.17E-050.0751488GMNCgeminin coiled-coil domain containing2.24E+ 001.52E-020.2689731A_33_P3274001NA2.24E+ 009.36E-050.0864965CRYGDcrystallin gamma D2.24E+ 002.58E-020.2964626**GREB1growth regulation by estrogen in breast cancer 12.22E+** **001.22E-030.1542519**[^15]Table 5The 50 Most Downregulated mRNAs in High PARP and Platinum Sensitive OC Patient Samples in Comparison to Low PARP and Platinum Resistant SamplesTable 5Gene NameGene DescriptionLog2-Fold Changep-Valueq-ValueEFEMP1EGF containing fibulin extracellular matrix protein 1−3.85E+ 001.50E-030.1587368FAPfibroblast activation protein alpha−3.66E+ 009.07E-040.1525447**TMOD1tropomodulin 1−3.41E+** **002.92E-080.0008577BNC1basonuclin 1−3.36E+** **002.74E-040.1050305**ENST00000453673NA−3.22E+ 002.22E-020.2877726ENST00000411475NA−3.18E+ 002.30E-020.2898232SCRG1stimulator of chondrogenesis 1−3.18E+ 001.64E-030.1627023PTGFRprostaglandin F receptor−3.04E+ 001.05E-030.1525447POSTNperiostin−3.01E+ 001.10E-020.2525629ENST00000390237NA−2.97E+ 001.54E-020.2695379BF175071NA−2.92E+ 005.12E-020.3538495**GUCY1A3guanylate cyclase 1 soluble subunit alpha−2.89E+** **005.68E-050.0723946**ENST00000390628NA−2.87E+ 004.44E-030.2021325CXCL13C-X-C motif chemokine ligand 13−2.87E+ 001.02E-020.2487313ACKR4atypical chemokine receptor 4−2.86E+ 009.73E-050.0864965IGLL5immunoglobulin lambda like polypeptide 5−2.86E+ 003.46E-020.318167AREGamphiregulin−2.83E+ 001.43E-020.2670241A_33_P3251412NA−2.81E+ 001.46E-020.2682963FYB1FYN binding protein 1−2.79E+ 002.51E-030.1843078CD38CD38 molecule−2.78E+ 001.54E-030.1587368ENST00000468879NA−2.77E+ 004.36E-020.3380632ENST00000390252NA−2.73E+ 001.49E-020.2682963JCHAINjoining chain of multimeric IgA and IgM−2.70E+ 006.61E-030.2195342ENST00000390547NA−2.69E+ 005.85E-030.2163421MEDAGmesenteric estrogen dependent adipogenesis−2.69E+ 004.49E-020.3403785CNR1cannabinoid receptor 1−2.68E+ 009.85E-030.2471112PRRX1paired related homeobox 1−2.68E+ 007.45E-040.1427284NR4A3nuclear receptor subfamily 4 group A member 3−2.67E+ 002.00E-020.2850432CH25Hcholesterol 25-hydroxylase−2.65E+ 002.21E-030.1762175AB363267NA−2.65E+ 004.23E-020.3347815ENST00000426099NA−2.63E+ 004.11E-020.331398CCL18C-C motif chemokine ligand 18−2.57E+ 001.16E-040.0898927THBS2thrombospondin 2−2.57E+ 003.91E-020.327707ENST00000410078NA−2.56E+ 005.30E-020.3580372BCHEbutyrylcholinesterase−2.55E+ 001.00E-020.2471753**ATP6V1DATPase H+ transporting V1 subunit D−2.55E+** **001.54E-040.1028588**ENST00000390323NA−2.55E+ 002.42E-020.2937808CCR2C-C motif chemokine receptor 2−2.54E+ 009.37E-030.24523ENST00000479981NA−2.54E+ 009.43E-030.24523**CASTcalpastatin−2.54E+** **001.02E-030.1525447**ASPNasporin−2.52E+ 002.94E-020.3049408HBBhemoglobin subunit beta−2.52E+ 002.08E-020.2862875ENST00000390247NA−2.51E+ 002.16E-020.2871745SULF1sulfatase 1−2.50E+ 001.80E-020.2805948EPYCepiphycan−2.49E+ 001.28E-020.2588936FGFBP1fibroblast growth factor binding protein 1−2.49E+ 001.03E-020.2499163LRRC15leucine rich repeat containing 15−2.48E+ 004.14E-020.3321649DOCK11dedicator of cytokinesis 11−2.45E+ 005.13E-040.1261184OOEPoocyte expressed protein−2.45E+ 004.23E-030.2013983**ROR2receptor tyrosine kinase like orphan receptor 2−1.84E+** **002.83E-050.0506967**[^16]Figure 1a. Scatterplot showing location of samples of high PARP and platinum sensitive and low PARP and platinum resistant in patients along the first two principal components (PC1 and PC2). Platinum sensitive and high PARP level samples are represented by black and low PARP and platinum resistant samples by purple dots.b. Unsupervised clustering of the clinical samples shows differential expression patterns in patients with high PARP levels and platinum sensitivity compared to patients with low PARP levels and platinum resistant.Figure 1

*GREB1* and *ROR2* are Significantly Differentially Expressed in Ovarian Cancer Tumor Samples Based on Platinum Sensitivity and PARP Levels {#s0060}
-------------------------------------------------------------------------------------------------------------------------------------------

Fourteen differentially expressed mRNAs (namely: *ROR2, CAST, ATP6V1D, GUCY1A3, TMOD1, MYCN, DLK1, PLEKHG4B, GREB1, B4GALNT4, SLC35F3, PTCH2, TNNC1, BNC1*) from the microarray analysis were selected for validation by qRT-PCR in the cohort of 53 ovarian cancer patients, based on fold change, q-value, signal intensity and previous literature ([Table 2](#t0010){ref-type="table"}). Two genes, namely *ROR2* and *GREB1*, were significantly differentially expressed in high PARP/platinum-sensitive vs. low PARP/platinum-resistant groups (*P* = .02 and 0.002, respectively) ([Figure 2](#f0010){ref-type="fig"}, a-b). *ROR2* was downregulated in microarray data in high PARP/platinum-sensitive tumor samples and the same result was obtained by qRT-PCR analysis in the validation cohort (n = 53). A trend towards statistically significant difference between the platinum sensitive and resistant groups regardless of PARP levels was observed (*P* = .058) ([Figure 2](#f0010){ref-type="fig"}a). The comparisons described above were based on treatment response as a significant clinical feature and issue of interest. In addition, previously determined PARP levels were taken into account to further investigate tumors from the BRCAness profile point of view. The platinum sensitive and high PARP level cohort is considered a group of better prognosis befitting with the BRCAness profile, whereas the platinum resistant and low PARP level a group with poorer prognosis.Figure 2a. Expression of ROR2 and GREB1 in platinum sensitive (n = 38) vs resistant (n = 15) samples as well as high PARP level and platinum sensitive (n = 17) vs low PARP level and platinum resistant (n = 14) samples according to qRT-PCR (*P* = .02 and 0.002 respectively). The graphs show mean ± SEM.b. Kaplan--Meier analysis of progression free survival (PFS) according to median level of GREB 1 concentration (log rank *P* = .019). Vertical lines represent censored patients.c. Kaplan--Meier analysis of progression free survival (PFS) according to median level of GREB 1 concentration (log-rank *P* = .014) from Kaplan--Meier plotter database.Figure 2

On the other hand, *GREB1* was upregulated in microarray data in high PARP/platinum-sensitive tumor samples, and this result was validated by qRT-PCR ([Figure 2](#f0010){ref-type="fig"}b). Furthermore, GREB1 also showed a trend of overexpression in platinum sensitive samples, regardless of PARP level (*P* = .26).

*GREB1* Expression Defines Platinum Sensitivity and Correlates with Longer PFS in Ovarian Cancer {#s0065}
------------------------------------------------------------------------------------------------

Furthermore, we investigated whether *GREB1* expression affects PFS in ovarian cancer patients (n = 53). High *GREB1* expression was significantly associated with longer PFS as shown in [Figure 2](#f0010){ref-type="fig"}c (*P* = .019 in log-rank test). In Kaplan--Meier database search, which included 1465 ovarian cancer patients, a similar result was shown associating high GREB1 expression with better PFS (*P* = 0,014 in log-rank test), as shown in [Figure 2](#f0010){ref-type="fig"}d. In addition to Kaplan--Meier plotter database and Oncomine (website links are reported in statistical analysis section) were searched for the *ROR2* and *GREB1* genes. No similar results in expression correlation were found, however, no similar study settings were found (HGSC, treatment response comparison).

High ROR2 Expression in LowPARP/Platinum Resistant Ovarian Cancer Samples Correlated with Higher Wnt5a, STAT3 and NF-kB levels {#s0070}
------------------------------------------------------------------------------------------------------------------------------

Previous data have shown no association with ROR2 expression and relapse-free survival [@bb0125] in ovarian cancer. However, ROR2 and ROR1 expression is increased in cisplatin resistant A2780 cell line compared to parental cells ([@bb0090]), and silencing their ligand Wnt5a in serous adenocarcinoma OVCAR3 cell line had greater effect in inhibiting cell migration and invasion than silencing either ROR alone [@bb0125]. Since *ROR2* was significantly upregulated in low PARP/platinum-resistant patient samples in our microarray data, we decided to investigate the expression levels of Wnt5a, ROR1 and ROR2 proteins by Western blot in a subcohort of samples described in [Table 3](#t0015){ref-type="table"}. As shown in [Figure 3](#f0015){ref-type="fig"}a-b, higher expression levels of Wnt5a, ROR1 and ROR2 proteins were found in low PARP/platinum-resistant group compared to high PARP/platinum-sensitive group. Moreover, upregulation of downstream signaling mediators such as pSTAT3 (Y705) and NF-kB was also observed in tumor lysates from low PARP/platinum resistant group. Noteworthy, patient samples with high levels of ROR1 and ROR2 from low PARP/platinum-resistant group showed higher pSTAT3 (Y705) levels ([Figure 3](#f0015){ref-type="fig"}a), indicating that STAT3 could mediate signaling downstream ROR1 and ROR2. Database search (Oncomine, Kaplan--Meier plotter; website links are reported in statistical analysis section) revealed no additional information regarding ROR in therapy response and ovarian cancer setting.Figure 3Wnt5a/ROR2 expression is increased in lysates from platinum resistant tumors. A. Western blot analysis of lysates from platinum resistant vs. platinum sensitive patient samples with the indicated primary antibodies. B. Quantification of protein expression for Wnt5a, ROR2, STAT3 and NF-kB based on β-tubulin levels. Horizontal lines represent the average and errors bars are SEM (standard error of mean). After normalization, samples were quantified based on the highest expression level of all samples.Figure 3

ROR2 and GREB1 Show Differential Expression in Cisplatin Resistant Ovarian Cancer Cell Line Model {#s0075}
-------------------------------------------------------------------------------------------------

The human epithelial ovarian cancer cell line A2780 and its cisplatin resistant model A2780cis were selected to investigate the expression levels of ROR2 and GREB1. We confirmed the chemoresistant phenotype of A2780cis cells compared to A2780 parental cells by CTG assay and found significant increase of EC50 to cisplatin treatment for A2780cis cells ([Figure 4](#f0020){ref-type="fig"}a). The expression of both ROR2 and GREB1 mRNA level was investigated in A2780 and A2780cis cells ([Figure 4](#f0020){ref-type="fig"}b and c). We observed ROR2 mRNA upregulation in platinum resistant cell line A2780cis compared to platinum sensitive A2780 cells (*P* = .0046), as previously shown ([@bb0090]), whereas GREB1 mRNA level was downregulated in A2780cis compared to A2780 parental cells (*P* = .0012). Furthermore, A2780cis cells have increased protein expression levels of ROR2 and Wnt5a compared with the parental A2780 cells as shown by Western blotting of cytoplasmic cell lysates ([Figure 4](#f0020){ref-type="fig"}d). In addition, we detected higher nuclear expression levels for STAT3 and NF-kB in chemoresistant A2780cis compared to parental A2780 cells ([Figure 4](#f0020){ref-type="fig"}d). Thus, our microarray data from patient samples are validated in chemoresistant ovarian cancer cell line and investigations are ongoing to decipher the molecular mechanisms employed by ROR2 and GREB1 for their differential expression associated with cisplatin resistance.Figure 4a. Cisplatin sensitivity testing of A2780 and A2780cis cell lines. Cells were incubated as five replicates for 3 days with increased concentrations of cisplatin as indicated and cell-viability was measured by CTG assay. EC50 was calculated using Graph Prism software and shown as approximate values.b. ROR2 mRNA expression in platinum sensitive and resistant cell lines A2780/A2780cis (*P* = .0046). The graphs show mean ± SEM.c. GREB1 mRNA expression in platinum sensitive and resistant cell lines A2780/A2780cis (*P* = .0012. The graphs show mean ± SEM.d. Protein expression levels for ROR2, Wnt5a, NF-kB and STAT3 in the cytoplasmic and nuclear cell lysates of A2780 and A2780cis cell lines. Protein quantification was done using Oddyssey Licor software and normalized against the loading control.Figure 4

Discussion {#s0080}
==========

Due to its poor prognosis, identification of new therapeutic approaches is highly needed in ovarian cancer. Although approximately 50% of HGSC tumors with HR defects may benefit from PARP inhibitors, beyond this, identification of other commonly deregulated pathways could provide opportunities for better therapeutic interventions. As such, our goal was to examine gene and protein expression in a HGSC tumor sample cohort defined by response to platinum therapy and the level of PARP expression. Patients were carefully stratified based on their PARP levels and platinum responsiveness as previously indicated [@bb0100] and monitored for relatively long time, up to 50 months to ensure a comprehensive analysis of their disease progression.

Two functionally unrelated genes, *GREB1* and *ROR2* were identified in our analysis as significantly differentially expressed between high PARP/platinum-sensitive and low PARP/platinum-resistant groups.

While initially sequenced from brain tissue, human *GREB1* is highly expressed in normal and neoplastic ovarian tissue and in several other hormone-responsive tissues such as breast, uterine and prostate [@bb0130], [@bb0135], [@bb0140], [@bb0145]. *GREB1*, along with *CCND1* and *MYC*, are common transcription targets for E2 (17β-estradiol)-mediated proliferative responses, via ESR1 (estrogen receptor one) engagement [@bb0140]. Estrogen receptor positive (ESR1^+,^) breast cancers usually express GREB1, whereas in ovarian cancer, its expression could be detected in both, ESR1^+^ or estrogen receptor negative (ESR1^−^) tumors. ESR1-independent expression of GREB1 may indicate the existence of other signaling pathways for estrogen-promoting growth in the absence of E2 and/or ESR1, underlining differences in E2-responsiveness between breast and ovarian cancer that play an important role in response to antiestrogenic therapies [@bb0150]. *GREB1* was upregulated in all EOC tumors and was suggested to have potential biomarker role in ovarian cancer [@bb0145]. *GREB1* was upregulated in our microarray data in high PARP/platinum-sensitive patients, and high *GREB1* expression was associated with longer PFS, suggesting a prognostic value for *GREB1* in ovarian cancer.

It has been demonstrated that *GREB*1 knockdown inhibits proliferation of ovarian cancer cell lines and consequently, prolongs survival in an orthotopic mouse model [@bb0140]. Also, hypomethylation at specific CpG site associated with *GREB1* has been associated with longer PFS in ovarian cancer in a DNA methylation study designed to investigate epigenetic modifications [@bb0155]. Interestingly, loss of GREB1 has been linked to tamoxifen resistance in breast cancer due to loss of sensitivity to endocrine agents in general, underlining its important role in endocrine resistance [@bb0160], [@bb0165]. Although endocrine therapy has overall limited efficacy in ovarian cancer patients, more research is needed to assess whether GREB1 is associated with antiestrogen sensitivity in this cancer. In view of this previous data, our results are in accordance with these findings reaffirming the understanding that *GREB1* is highly expressed in high PARP/platinum-sensitive patient group that has been associated with a positive outcome befitting with the BRCAness profile [@bb0050]. Our data show for the first time that *GREB1* could have prognostic value in ovarian cancer and warrants further investigation, especially associated with response to hormone-based therapy.

*ROR2* belongs to the ROR receptor family (*ROR1* and *ROR2*) from the non-canonical Wnt pathway [@bb0085]. ROR1 and ROR2 form heterodimers in response to Wnt5a, which leads to RhoA/Rac1 activation and increases migration and invasion properties of cancer cells [@bb0170]. Recent studies have demonstrated that upregulation of *ROR2* and its ligand Wnt5a in EOC regulates EMT and correlates with worse prognosis [@bb0175]. *ROR1* and *ROR2* regulate migration and invasion of ovarian cancer cells and more importantly, their expression was increased in platinum resistant A2780 ovarian cancer cell line compared to parental cells ([@bb0090]). TCGA data analysis of over 500 ovarian tumor samples identified high expression of Wnt5a and Wnt5a protein was found prevalent in ascites samples of ovarian cancer patients [@bb0180]. In our study, *ROR2* gene expression was significantly upregulated in low PARP/platinum-resistant vs. high PARP/platinum-sensitive patient samples. We also found higher protein levels of ROR2, ROR1 and Wnt5a ligand in lysates of platinum-resistant tumors ([Figure 3](#f0015){ref-type="fig"}, a-b), confirming our gene expression analysis. Interestingly, higher expression levels of NF-κB and pSTAT3 (Y705) proteins were also noted in platinum-resistant tumor lysate with high ROR1 and ROR2 levels, indicating that STAT3 could be downstream mediator of ROR signaling in ovarian cancer. These results showing Wnt5a-ROR2 and STAT3/NF-kB signaling pathway in clinical ovarian tumor samples are novel findings. A direct link between ROR1 and STAT3 expression has been demonstrated previously in leukemia, showing that STAT3 promoter harbors two ROR1 binding sites [@bb0185]. Moreover, previous studies have shown that Wnt5a is involved in cancer multidrug resistance (MDR)[@bb0180]. High Wnt5a expression levels in ovarian cancer cell lines correlated with lower chemosensitivity to paclitaxel, oxaliplatin, 5-fluorouracil, epirubicin and etoposide ([@bb0190], [@bb0195]. Furthermore, upregulation of Wnt5a and ROR2 was detected in colon cancer cells resistant to butyrate, a histone deacetylase inhibitor (HDACi)[@bb0200], along with activation of AKT/PKB (protein kinase B) signaling pathway. Wnt5a orchestrates multiple signaling networks involved in chronic inflammation and carcinogenesis, and crosstalk with STAT3 and NF-κB pathways have been previously documented [@bb0205]. Thus, upregulation of Wnt5a, ROR1 and ROR2 signaling pathways could be common mechanisms in ovarian cancer chemoresistance and could serve as putative biomarkers. ROR1 targeted therapies have shown promising results in preclinical and clinical models, with anti-ROR1 monoclonal antibody cirmtuzumab being efficient not only in leukemia, but also in ovarian cancer [@bb0210], indicative of high therapeutic potential for targeting these receptors.

Our mRNA expression data from patient samples were validated using a cisplatin resistant cell line model A2780cis and we found that upregulation of ROR2 at the mRNA and protein levels is associated with cisplatin resistance. Moreover, GREB1 mRNA level was downregulated in A2780cis compared to A2780 parental cells. Furthermore, we observed higher expression levels for Wnt5a, STAT3 and NF-kB proteins in chemoresistant A2780cis cells compared to parental cells, in support of our results from patient samples ([Figure 3](#f0015){ref-type="fig"}).

In conclusion, we found the expression of ROR2 and GREB1 to be associated with treatment response in HGSC. The association between Wnt5a/ROR2 expression and development of platinum resistance reported herein suggests that the Wnt5a/ROR2 pathway is potentially actionable for possible modulation of chemoresistance. Because silencing *ROR1* and *ROR2* restores the chemosensitivity of carboplatin-resistant ovarian cancer cells [@bb0090], a combination of ROR antagonists and chemotherapeutic agents may offer a promising treatment option. Also, our findings regarding *GREB1* expression in highPARP/platinum-sensitive patients should reinforce the interest in this gene for future investigations.
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[^1]: Equal contribution.

[^2]: Sensitivity defined as relapse or event-free interval\> 12 months after completion of platinum based 1st line therapy.

[^3]: PDS - primary debulking surgery.

[^4]: NACT - neoadjuvant therapy.

[^5]: PARP - PARP activity in fresh frozen tumor tissue was assessed by an enzymatic chemiluminescense assay in a previous study [@bb0100]; the cut-off level for high PARP activity was set to 203 pg/ml corresponding to median value.

[^6]: Grade -- Grade 3 represents high grade tumors.

[^7]: FIGO - International Federation of Gynecology.

[^8]: PFS - progression free survival.

[^9]: FIGO = International Federation of Gynecology.

[^10]: Grade -- Grade 3 represents high grade tumors, Grade 1 and 2 low grade tumors.

[^11]: Sensitive: Recurrence \>12 months after completion of platinum-based 1st line therapy; Resistant: Recurrence ≤6 months after completion of platinum-based 1st line therapy; Partially sensitive: Recurrence 6--12 months after completion of platinum-based 1st line therapy.

[^12]: FIGO = International Federation of Gynecology.

[^13]: Grade -- Grade 3 represents high grade tumors, Grade 1 and 2 low grade tumors.

[^14]: Sensitivity defined as relapse or event-free follow up time\> 12 months after completion of platinum based 1st line therapy.

[^15]: mRNAs selected for further validation are shown in bold.

[^16]: mRNAs selected for further validation are shown in bold.
